Hide filtersShow filters × Close Bryan, Garnier & Co acts as Sole Financial Advisor to Selfapy, one of the leading providers in digital therapeutics for mental health disorders in Germany, on its growth financing from strategic investor Medice Arzneimittel and existing shareholders Bryan, Garnier & Co acts as Sole Bookrunner on Oncodesign Precision Medicine’s EUR 8 million Follow-on Offering & IPO on Euronext Growth Paris Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on Nicox’ Euronext Paris EUR 10 million Follow-on Offering & Warrants issuance Bryan, Garnier & Co acts as Joint Bookrunner on Valneva’s Nasdaq and Euronext Paris EUR 102.9 million Follow-on Offering Bryan, Garnier & Co acts as Sole Global Coordinator and Joint Bookrunner on Abivax’s EUR 49 million Cross-over Financing Bryan Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Lhyfe on its landmark €110m IPO on Euronext Paris Bryan, Garnier & Co acts as Sole Financial Advisor to Enapter AG on a €20m strategic investment from Johnson Matthey Bryan, Garnier & Co acts as Sole Global Coordinator & Sole Bookrunner on GeNeuro EUR 7.7 million Follow-On Offering Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on Avantium’s Euronext Amsterdam EUR 45m Publicly Marketed Follow-On Offering Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on Aelis Farma’s Euronext Paris EUR 25m Initial Public Offering Bryan, Garnier & Co is proud to act as Joint Bookrunner to Cell Impact on its SEK 349m Rights Issue Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Nicox on its EUR 15 million Follow-on Offering of shares and warrants
